This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Sage Therapeutics Croissance future
Future contrôle des critères 2/6
Sage Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 25.4% et de 26% par an respectivement. Le BPA devrait croître de de 29.5% par an. Le rendement des capitaux propres devrait être -83.4% dans 3 ans.
Informations clés
25.4%
Taux de croissance des bénéfices
29.50%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.4% |
| Taux de croissance des recettes | 26.0% |
| Rendement futur des capitaux propres | -83.40% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 31 Jul 2025 |
Mises à jour récentes de la croissance future
Recent updates
Nouveau récit • Mar 29
Expanding ZURZUVAE Demand Will Improve Postpartum And Neuropsych Care
Establishing ZURZUVAE as the PPD care standard should drive top-line growth through increased demand and brand visibility.Seeking Alpha • Jan 22
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Summary Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for SAGE at $7.22 per share, which seems exceedingly cheap, considering SAGE has a lot of cash, and Zurzuvae is just ramping up its sales. SAGE is now contesting the takeover, which could lead to higher follow-up bids. This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime that provides quick relief for depressive symptoms. This is why I think SAGE stock is a good buy at these levels. It seems undervalued as a standalone company or a takeover target with BIIB. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Summary The company remains a "hold" due to Biogen's unsolicited offer to acquire shares at a 30% premium, despite pipeline setbacks. The failure of the phase 2 DIMENSION study for dalzanemdor in treating cognitive impairment in Huntington's Disease highlights Sage's shrinking pipeline. Sage's financials indicate a need for additional funding in 2025, risking dilution and further financial instability. The future of SAGE-324 and SAGE-319 remains uncertain in treating patients with neurodevelopmental disorders, adding risk to the company's long-term prospects. Read the full article on Seeking AlphaSeeking Alpha • Nov 19
CNS Drug Development: Same As It Ever Was
Summary Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as well. They have a clinical trial readout in Huntington's disease later this fall, and man, that's a tough place to make your stand. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Summary Sage Therapeutics is a "sell" due to the failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's Disease. Dalzanemdor's upcoming phase 2 studies for Huntington's and Alzheimer's diseases are unlikely to succeed, given prior trial results and similar primary endpoints. Financially, Sage has enough cash to operate until 2026, but without successful trials, raising additional funds will be challenging. Despite FDA approval of Zurzuvae for postpartum depression, it won't drive long-term growth; dalzanemdor's success is crucial for shareholder value creation. Read the full article on Seeking AlphaArticle d’analyse • Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Jul 25
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Summary Sage Therapeutics, Inc.'s SAGE-324 failed its Phase 2b trial for essential tremor and development is discontinued. Dalzanemdor's past data in Parkinson's casts doubt on its prospects in other cognitive disorders. Zurzuvae's Q1 revenue exceeded expectations, but the market potential remains constrained by its narrow indication. Analysts are expecting $8.90 million in revenue for Q2. While Sage may exceed this, it isn't likely to move the stock much. Given clinical setbacks and limited revenue growth, I recommend downgrading Sage Therapeutics to “sell.”. Read the full article on Seeking AlphaArticle d’analyse • Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Sage Therapeutics, Inc. ( NASDAQ:SAGE ) is a stock...Seeking Alpha • May 30
Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patients, expected in mid-2024. Top-line data from the phase 2 DIMENSION study, using SAGE-718 for cognitive impairment in HD patients, expected late-2024. Top-line data from the phase 2 LIGHTWAVE Study, using SAGE-718 for mild cognitive impairment or mild dementia due to Alzheimer's Disease, expected late-2024. Read the full article on Seeking AlphaArticle d’analyse • May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Article d’analyse • Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
The analysts covering Sage Therapeutics, Inc. ( NASDAQ:SAGE ) delivered a dose of negativity to shareholders today, by...Article d’analyse • Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Key Insights Sage Therapeutics' estimated fair value is US$29.43 based on 2 Stage Free Cash Flow to Equity Sage...Seeking Alpha • Jan 22
Sizing Up Sage Therapeutics
Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. The drug has just been launched and management has taken actions to substantially lower annual operating costs. What's ahead for Sage Therapeutics in 2024? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Today is shaping up negative for Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders, with the analysts delivering a...Article d’analyse • Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Today we will run through one way of estimating the intrinsic value of Sage Therapeutics, Inc. ( NASDAQ:SAGE ) by...Article d’analyse • Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 02
Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Sage Therapeutics press release (NASDAQ:SAGE): Q2 GAAP EPS of -$2.13 beats by $0.02. Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M. Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022 Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022 Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025Article d’analyse • Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 24
Sage Therapeutics: Well-Funded But Uninspiring Data
Sage is well funded by Biogen. However, lead candidate SAGE-217 has not come up with strong MDD data. I continue to sit on the fence.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 164 | -151 | -111 | -63 | 11 |
| 12/31/2026 | 121 | -194 | -221 | -163 | 14 |
| 12/31/2025 | 84 | -223 | -227 | -214 | 7 |
| 6/30/2025 | 70 | -301 | -289 | -289 | N/A |
| 3/31/2025 | 47 | -354 | -311 | -311 | N/A |
| 12/31/2024 | 41 | -401 | -267 | -267 | N/A |
| 9/30/2024 | 106 | -338 | -320 | -320 | N/A |
| 6/30/2024 | 97 | -446 | -374 | -374 | N/A |
| 3/31/2024 | 91 | -503 | -425 | -425 | N/A |
| 12/31/2023 | 86 | -541 | -541 | -541 | N/A |
| 9/30/2023 | 11 | -656 | -549 | -548 | N/A |
| 6/30/2023 | 10 | -592 | -532 | -531 | N/A |
| 3/31/2023 | 9 | -558 | -507 | -506 | N/A |
| 12/31/2022 | 8 | -533 | -461 | -460 | N/A |
| 9/30/2022 | 6 | -510 | -432 | -431 | N/A |
| 6/30/2022 | 6 | -503 | -381 | -381 | N/A |
| 3/31/2022 | 6 | -484 | -377 | -377 | N/A |
| 12/31/2021 | 6 | -458 | -379 | -378 | N/A |
| 9/30/2021 | 1,114 | 642 | 730 | 730 | N/A |
| 6/30/2021 | 1,114 | 666 | 708 | 708 | N/A |
| 3/31/2021 | 1,113 | 637 | 692 | 692 | N/A |
| 12/31/2020 | 1,114 | 606 | 664 | 664 | N/A |
| 9/30/2020 | 7 | -537 | -464 | -463 | N/A |
| 6/30/2020 | 9 | -612 | -504 | -501 | N/A |
| 3/31/2020 | 9 | -644 | -520 | -515 | N/A |
| 12/31/2019 | 7 | -680 | -534 | -529 | N/A |
| 9/30/2019 | 5 | -670 | -520 | -514 | N/A |
| 6/30/2019 | 2 | -613 | -470 | -465 | N/A |
| 3/31/2019 | 91 | -462 | N/A | -332 | N/A |
| 12/31/2018 | 90 | -373 | N/A | -261 | N/A |
| 9/30/2018 | 90 | -284 | N/A | -218 | N/A |
| 6/30/2018 | 90 | -235 | N/A | -184 | N/A |
| 3/31/2018 | N/A | -288 | N/A | -243 | N/A |
| 12/31/2017 | N/A | -270 | N/A | -219 | N/A |
| 9/30/2017 | N/A | -257 | N/A | -194 | N/A |
| 6/30/2017 | N/A | -221 | N/A | -179 | N/A |
| 3/31/2017 | N/A | -185 | N/A | -146 | N/A |
| 12/31/2016 | N/A | -159 | N/A | -119 | N/A |
| 9/30/2016 | N/A | -132 | N/A | -103 | N/A |
| 6/30/2016 | N/A | -118 | N/A | -92 | N/A |
| 3/31/2016 | N/A | -108 | N/A | -84 | N/A |
| 12/31/2015 | N/A | -94 | N/A | -71 | N/A |
| 9/30/2015 | N/A | -78 | N/A | -61 | N/A |
| 6/30/2015 | N/A | -64 | N/A | -49 | N/A |
| 3/31/2015 | N/A | -47 | N/A | -36 | N/A |
| 12/31/2014 | N/A | -36 | N/A | -27 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: SAGE devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: SAGE devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: SAGE devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de SAGE ( 26% par an) devrait croître plus rapidement que le marché US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de SAGE ( 26% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: SAGE devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2025/08/01 05:06 |
| Cours de l'action en fin de journée | 2025/07/30 00:00 |
| Les revenus | 2025/06/30 |
| Revenus annuels | 2024/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Sage Therapeutics, Inc. est couverte par 9 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |